Regulus Therapeutics
RGLS
#7320
Rank
ยฃ0.42 B
Marketcap
ยฃ6.10
Share price
0.00%
Change (1 day)
428.03%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -ยฃ36.82 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -ยฃ34.54 Million a decrease over its 2023 earnings that were of -ยฃ22 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -ยฃ36.82 Million6.6%
2024 -ยฃ34.54 Million56.97%
2023 -ยฃ22 Million6.51%
2022 -ยฃ20.66 Million2.53%
2021 -ยฃ20.15 Million93.59%
2020 -ยฃ10.41 Million-15.41%
2019 -ยฃ12.31 Million-64.46%
2018 -ยฃ34.62 Million-33.26%
2017 -ยฃ51.86 Million-13.98%
2016 -ยฃ60.29 Million44.77%
2015 -ยฃ41.65 Million-1.63%
2014 -ยฃ42.34 Million203.6%
2013 -ยฃ13.95 Million8.65%
2012 -ยฃ12.84 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
ยฃ5.35 B-15,196.86%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
ยฃ0.75 B-2,232.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ8.90 B-25,211.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ10.71 B-30,317.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
ยฃ5.89 B-16,734.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-ยฃ82.47 Million 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-ยฃ87.95 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
ยฃ0.84 B-2,471.21%๐Ÿ‡บ๐Ÿ‡ธ USA